Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bora Lim

Showing results (91-100 of 147) with videos related to

Pageof 15
Sort By:
Plos One|May 1, 2020
Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational researchJose Rodrigo Espinosa Fernandez, Bedrich L Eckhardt, Jangsoon Lee, et al.
The Oncologist|February 1, 2020
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without TrastuzumabTakahiro Kogawa, Takeo Fujii, Jimin Wu, et al.
Science Advances|March 29, 2023
Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studiesDaniel Wang, Caroline E Porter, Bora Lim, et al.
Biochemical and Biophysical Research Communications|February 20, 2019
Prognostic significance of high metabolic activity in breast cancer: PET signature in breast cancerSanghee Kang, Eui Hyun Kim, Jun-Eul Hwang, et al.
Science Advances|June 30, 2023
Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsivenessElena Oropeza, Sinem Seker, Sabrina Carrel, et al.
Oncogene|February 22, 2023
Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatmentMokryun L Baek, Junegoo Lee, Katherine E Pendleton, et al.
Oncotarget|February 23, 2018
Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancerTeruo Yamauchi, Jose Rodrigo Espinosa Fernandez, Chiyo K Imamura, et al.
Cancer Medicine|December 19, 2019
Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancerNaoto T Ueno, Rie K Tahara, Takeo Fujii, et al.
Investigational New Drugs|September 28, 2020
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancerClinton Yam, Gaiane M Rauch, Tanbin Rahman, et al.
Cell Reports|September 14, 2022
BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancerGonghong Yan, Augustin Luna, Heping Wang, et al.
Pageof 15

Showing results (91-100 of 147) with videos related to

Sort By:
Pageof 15
Plos One|May 1, 2020
Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational researchJose Rodrigo Espinosa Fernandez, Bedrich L Eckhardt, Jangsoon Lee, et al.
The Oncologist|February 1, 2020
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without TrastuzumabTakahiro Kogawa, Takeo Fujii, Jimin Wu, et al.
Science Advances|March 29, 2023
Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studiesDaniel Wang, Caroline E Porter, Bora Lim, et al.
Biochemical and Biophysical Research Communications|February 20, 2019
Prognostic significance of high metabolic activity in breast cancer: PET signature in breast cancerSanghee Kang, Eui Hyun Kim, Jun-Eul Hwang, et al.
Science Advances|June 30, 2023
Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsivenessElena Oropeza, Sinem Seker, Sabrina Carrel, et al.
Oncogene|February 22, 2023
Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatmentMokryun L Baek, Junegoo Lee, Katherine E Pendleton, et al.
Oncotarget|February 23, 2018
Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancerTeruo Yamauchi, Jose Rodrigo Espinosa Fernandez, Chiyo K Imamura, et al.
Cancer Medicine|December 19, 2019
Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancerNaoto T Ueno, Rie K Tahara, Takeo Fujii, et al.
Investigational New Drugs|September 28, 2020
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancerClinton Yam, Gaiane M Rauch, Tanbin Rahman, et al.
Cell Reports|September 14, 2022
BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancerGonghong Yan, Augustin Luna, Heping Wang, et al.
Pageof 15